Medicare Advantage Newsfeed

GoHealth filed prepackaged Chapter 11 bankruptcy on June 12, 2026, handing control to lenders amid revenue collapse and rising losses in 2025. The move represents a decisive exit by a major Medicare Advantage distribution platform with significant customer acquisition exposure.

GoHealth's failure signals severe structural stress in independent MA broker distribution (CAC inflation, commission compression). This opens consolidation opportunities for surviving brokers (eHealth, SelectQuote, Integrity, Chapter) and reinforces payer preference for captive or owned-and-operated channels.

Federal OIG issued report documenting that major Medicare Advantage plans (UnitedHealth, Humana, Aetna among others named) systematically deny skilled nursing and rehabilitation care prior authorizations at unusually high rates, later overturning most denials on appeal. Report flagges patterns suggesting denial-for-profit behavior.

This regulatory spotlight creates imminent Congressional and CMS enforcement risk for named payers. It validates beneficiary complaints, may trigger stricter prior authorization rules, and raises reputational/litigation exposure. Likely to drive policy tightening on MA medical necessity standards and appeal timelines.

Clover Health prevailed in a court challenge to CMS star ratings, leading CMS to upgrade its Medicare Advantage PPO (covering 97% of members) from 4.0 to 4.5 stars. Stock surged ~14% on the news, signaling material revenue impact from improved bonus payments.

This court-triggered star rating reset creates a precedent for challenging CMS methodology and raises questions about the robustness of the star ratings framework itself. For Clover specifically, the upgrade materially improves 2027 quality bonus revenue, improving path to profitability and reducing dilution risk.

CMS announced 2027 Medicare Advantage rate increase of 2.48% average revenue per member, significantly above the initially projected 0.09%. Plans submitted bids last week; rate signal suggests medical trend moderation and improved rate adequacy versus 2025-2026 crisis.

The rate beat reduces (but does not eliminate) incentive for aggressive benefit cuts, network curation, and market exits in 2027. Industry sources expect continued portfolio reshuffling and targeted exits (e.g., Presbyterian Health Plan in NM, Providence Health Plan in WA already announced), but less dramatic than 2026. Enrollment growth may stabilize rather than decelerate further.

Congressional Joint Economic Committee released analysis estimating CMS overpays Medicare Advantage plans by $7 billion annually and the amount is rising. Report underscores structural rate-setting inefficiencies and misalignment between MA and FFS costs.

This Congressional finding intensifies pressure on CMS to tighten rate-setting methodologies and risk adjustment models (RADV audits, HCC audits). Creates bipartisan political cover for rate reductions in future years and may accelerate regulatory scrutiny of MLR, coding practices, and risk adjustment inflation.

Elevance Health (ELV) faces a material CMS Medicare compliance deadline in late June 2026, with investor and analyst focus intensifying on regulatory overhang. Stock has been under pressure as investors refocus on the compliance risk.

Elevance's regulatory exposure (likely tied to network adequacy, prior authorization, or rate-setting compliance) creates material downside risk to 2027 guidance and capitated margins. Any CMS enforcement action (audit, corrective action plan, penalties) could cascade across the MA portfolio and competitor portfolios.

Humana reportedly lost a Medicare Star Ratings lawsuit against CMS, coinciding with Clover's successful court challenge. These competing outcomes raise fundamental questions about the robustness and defensibility of CMS's star ratings methodology.

The divergent court outcomes (Humana loses, Clover wins) signal that CMS's star ratings determinations are increasingly subject to judicial review and may be vulnerable to legal challenge. This creates uncertainty for all payers on the stability of their 2027 quality bonus payments and potential retroactive adjustments.

Sagility announced acquisition of CareSeed to expand AI-powered quality operations and Medicare Advantage capabilities. CareSeed specializes in MA quality metrics, RADV audit prep, and compliance automation.

This M&A signals consolidation in MA-specific technology services and reflects payer demand for AI-driven quality and risk adjustment tools to combat RADV audit risk and optimize star ratings. Trend accelerates vertical integration of MA operations tech.

Major health systems (Fairview in Minnesota, Brown Health) announced they will not accept or continue serving UnitedHealthcare Medicare Advantage beneficiaries in 2026-2027. Network departures reflect payer-provider contract disputes and reimbursement tensions.

Network defections by tier-1 health systems signal escalating payer-provider tension over MA reimbursement adequacy and contract terms. UNH's aggressive MA margins and prior authorization practices may be driving strategic provider exits, creating member access risk and competitive vulnerability.

Humana announced sale of its Gentiva Health Services stake in a $900M deal, further retreating from integrated health services and provider-sponsored models. Move reflects prior consolidation missteps and refocus on payer core.

Divestiture signals Humana's strategic pivot away from vertically integrated provider-payer models and validates shift toward asset-light MA platforms. May free capital for share buybacks or balance sheet strengthening ahead of 2027 MA competition.

CMS has signaled or proposed new rules that will restrict or eliminate certain non-medical supplemental benefits (e.g., meal delivery, transportation, social services) in Medicare Advantage plans. Plans are preparing to reduce these benefits in 2027.

Benefit cuts will reduce MA plan attractiveness relative to traditional Medicare and narrow cost advantage vs. competitor plans. However, reduced supplemental benefit costs will improve plan MLR and margins. Beneficiary satisfaction and enrollment growth may face headwinds, particularly among lower-income and D-SNP populations.

Alignment Healthcare (ALHC) stock jumped 25% following governance changes and positive MA market signals. Company is repositioning for aggressive MA enrollment growth amid industry consolidation.

ALHC's momentum reflects investor appetite for pure-play MA growth stories with improving unit economics. Stock move signals market recognition of Alignment's scale advantage and potential acquisition target status for larger payers.

Prior authorization reform bill became eligible for House fast-track consideration in late June 2026, signaling Congressional momentum on reducing denial abuse in MA and commercial plans. Bill likely to include strict timelines and penalties for untimely denials.

Fast-track eligibility signals likely passage and imminent regulatory tightening on MA prior authorization processes. MA payers will face stricter appeal timelines, mandatory reversal of certain denials, and potential penalties. This will pressure margins on high-utilization populations and increase operational complexity.

KFF issued analysis documenting how Medicare Advantage plans' ability to lower Part D premiums or eliminate cost sharing via rebates has destabilized the standalone drug plan (PDP) market, creating competitive imbalance and driving PDP consolidation.

KFF analysis validates structural concern that MA's integrated drug benefit advantage (rebate pass-through) is hollowing out PDP market, creating reliance on MA for drug coverage. This accelerates beneficiary concentration in MA and raises regulatory/Congressional concerns about market structure.